Pathology: metastatic/advanced OC (mOC) - 2nd line (L2); metastatic/advanced OC (mOC) - maintenance (M); mOC - L1 - all population; mOC - L1 - PDL1 positive;
| metastatic/advanced OC (mOC) - 2nd line (L2) | metastatic/advanced OC (mOC) - maintenance (M) | mOC - L1 - all population | mOC - L1 - PDL1 positive | ||||
| JAVELIN ovarian 200 (A vs doxorubicin), 2021 | JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 | NRG GY003, 2020 | JAVELIN Ovarian 100, 0 | IMagyn-050 (all population), 2021 | IMagyn-050 (PDL1 >1%), 2021 | ||
| atezolizumab plus SoC | 2 | T1 | T1 | ||||
| avelumab plus SoC | 1 | T1 | |||||
| avelumab alone | 1 | T1 | |||||
| avelumab plus pegylated liposomal doxorubicin | 1 | T1 | |||||
| nivolumab plus ipilimumab | 1 | T1 | |||||
| Standard of Care (SoC) | 0 | T0 | |||||
| pegylated liposomal doxorubicin | 0 | T0 | T0 | ||||
| placebo plus SoC | 0 | T0 | T0 | ||||
| nivolumab alone | 0 | T0 | |||||